Brief: TG Therapeutics Announces Phase 1 Data Evaluating Azer-Cel In Progressive Multiple Sclerosis
Today 16:03
BRIEF-TG Therapeutics Announces Phase 1 Data Evaluating Azer-Cel In Progressive Multiple Sclerosis Oct 23 (Reuters) - TG Therapeutics, Inc. TGTX.O:
TG THERAPEUTICS ANNOUNCES PHASE 1 DATA EVALUATING AZER-CEL IN PROGRESSIVE MULTIPLE SCLEROSIS IN A LATE-BREAKING ORAL PRESENTATION AT MSTORONTO2026
TG THERAPEUTICS INC: PHASE 1 DATA SHOWS 89% OF EVALUABLE PARTICIPANTS HAD STABLE OR IMPROVED DISABILITY SCORES AT DAY 90
TG THERAPEUTICS: AZER-CEL SHOWED ENCOURAGING INITIAL SAFETY PROFILE IN 26 PEOPLE, NO DOSE-LIMITING TOXICITIES, HIGH-GRADE CAR T ASSOCIATED TOXICITIES
Source text: ID:nBw3NLmvTa
Further company coverage: TGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsBrief: TG Therapeutics Announces Phase 1 Data Evaluating Azer-Cel In Progressive Multiple Sclerosis
TG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj